Norges Bank Seagen Inc. Transaction History

Norges Bank

$634 Trillion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $364 Million - $411 Million	-1,899,159 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $322 Million - $353 Million	-1,713,639 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$127.59 - $203.08 $255 Million - $405 Million	1,996,522 New	1,996,522 $404 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $257 Million - $304 Million	2,187,105 New	2,187,105 $281 Million
Q3 2022 Nov 13, 2023	BUY	$135.27 - $180.11 $257 Million - $342 Million	1,899,159 New	1,899,159 $260 Million

Q2 2022 Aug 14, 2023	BUY	$108.81 - $179.33 $186 Million - $307 Million	1,713,639 New	1,713,639 $303 Million
Q1 2022 May 12, 2023	SELL	$119.61 - $157.85 $35.7 Million - $47.1 Million	-298,459 Reduced 13.65%	1,888,646 $272 Million
Q1 2022 May 09, 2022	SELL	$119.61 - $157.85 $208 Million - $274 Million	-1,735,414 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$142.57 - $190.86 $247 Million - $331 Million	1,735,414 New	1,735,414 $268 Million
Q3 2021 Nov 14, 2022	BUY	$142.45 - $169.82 $222 Million - $264 Million	1,555,290 New	1,555,290 $264 Million
Q3 2021 Nov 05, 2021	SELL	$142.45 - $169.82 $201 Million - $239 Million	-1,409,376 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$135.08 - $161.1 $190 Million - $227 Million	1,409,376 New	1,409,376 $223 Million
Q2 2021 Aug 10, 2021	SELL	$135.08 - $161.1 $192 Million - $228 Million	-1,417,890 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$137.51 - $190.8 $195 Million - $271 Million	1,417,890 New	1,417,890 $197 Million
Q1 2021 May 07, 2021	SELL	$137.51 - $190.8 $181 Million - $252 Million	-1,319,525 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$164.63 - $211.93 $217 Million - $280 Million	1,319,525 New	1,319,525 $231 Million

Others Institutions Holding SGEN

# of Institutions

Shares Held

1.26M

Call Options Held

23K

Put Options Held

55.2K

View Full List

About Seagen Inc.

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

More about SGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account